This article summarizes the role of PET imaging for detection, characterization, and theranostic/therapy planning for neuroendocrine tumors. Topics in this article span overall imaging accuracy with mostly 68Ga-DOTA-peptide imaging as well as basic principles of individualized dosimetry. There is also some discussion around further specialized approaches in dosimetry in theranostics. In addition, an overview of the literature on functional imaging in neuroendocrine tumors and the current understanding of imaging-derived clinical outcome prediction are presented.
Keywords: 68-Gallium DOTA-peptides; Dosimetry; Neuroendocrine tumors; Outcome prediction; PET imaging; Theranostic.
Copyright © 2021 Elsevier Inc. All rights reserved.